Vera Therapeutics, Inc. (VERA)
NGM – Real vaqt narxi. Valyuta: USD
37.69
+0.99 (2.70%)
Bozor ochiq: May 13, 2026, 9:54 AM EDT
Find any stock by ticker or company name

NGM – Real vaqt narxi. Valyuta: USD
37.69
+0.99 (2.70%)
Bozor ochiq: May 13, 2026, 9:54 AM EDT
Vera Therapeutics, Inc., klinik bosqichdagi biotexnologiya kompaniyasi, immunologik kasalliklarga chalingan bemorlar uchun transformativ davolash usullarini ishlab chiqish va tijoratlashtirishga qaratilgan. Kompaniya to'liq insonlashtirilgan TACI-Fc chimera oqsilini, ya'ni B-hujayralar faollashtiruvchi omil (BAFF) va proliferatsiyani rag'batlantiruvchi ligand (APRIL) ga bog'lanadigan atakiceptni taklif etadi, u uyda teri ostiga in'ektsiya sifatida o'z-o'zidan yuboriladi va immunoglobulin A nefropatiyasi (IgAN) va boshqa otoimmün buyrak kasalliklarini davolash uchun baholanmoqda. Shuningdek, u 2-bosqich klinik sinovini yakunlagan BK virusli infektsiyalarini davolash uchun inson monoklonal antitelosi bo'lgan MAU868 va B-hujayralari vositasidagi otoimmün kasalliklarni davolash uchun BAFF/APRIL ikkilamchi inhibitörlü B-hujayralarining etuklik antijeni (BCMA) molekulasi bo'lgan VT-109ni ishlab chiqmoqda. Kompaniya avval Trucode Gene Repair, Inc. nomi bilan tanilgan va 2020-yil aprel oyida Vera Therapeutics, Inc. nomini o'zgartirgan. Vera Therapeutics, Inc. 2016-yilda tashkil etilgan va uning bosh qarorgohi Kaliforniyaning Brisben shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Jane Wright-Mitchell J.D., Pharm.D. | Chief Legal Officer & Secretary |
| Dr. Marshall W. Fordyce M.D. | Founder, President, CEO & Director |
| Dr. Robert M. Brenner M.D. | Chief Medical Officer |
| Mr. David L. Johnson M.B.A. | Chief Opearating Officer |
| Mr. Joseph R. Young M.B.A. | Senior VP of Finance & Chief Accounting Officer |
| Mr. Sean P. Grant M.B.A. | Chief Financial Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-07 | 8-K | vera-20260507.htm |
| 2026-05-07 | 10-Q | vera-20260331.htm |
| 2026-04-09 | DEFA14A | ny20065346x2_defa14a.htm |
| 2026-04-09 | ARS | ny20065346x3_ars.pdf |
| 2026-03-09 | 8-K | vera-20260305.htm |
| 2026-02-27 | S-8 | d75687ds8.htm |
| 2026-02-26 | 8-K | vera-20260226.htm |
| 2026-02-26 | 10-K | vera-20251231.htm |
| 2025-12-18 | 8-K | d26538d8k.htm |
| 2025-12-10 | 8-K | d870139d8k.htm |
| Mr. William D. Turner | Chief Regulatory Officer |
| Ms. Debra Charlesworth | Vice President of Corporate Communications |
| Ms. Emma Haywood | Vice President of Marketing |
| Ms. S. Sandra Park J.D. | Senior VP of Legal, Healthcare,Commercial Law, Compliance & Operations |